Clareo Health | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Blueprint Medicines Corporation
With
Analysis Group, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have a diagnosis of locally advanced (non-resectable) or metastatic RET-fusion positive NSCLC
Must have received at least one line of systemic therapy for locally advanced (non-resectable) or metastatic RET-fusion positive NSCLC, which may include regimens containing:
* Chemotherapy in combination with other drugs will be assessed, e.g., in combination with pemetrexed, immune checkpoint inhibitors (pembrolizumab), bevacizumab
* Ramucirumab in combination with docetaxel
* Immune checkpoint inhibitors, e.g., pembrolizumab, nivolumab, and atezolizumab
* MKIs, e.g., cabozantinib, alectinib, vandetanib, sunitinib, and nintedanib
Must be aged ≥18 years of age at the initiation of first systemic line of therapy
Must have availabile of performance status (e.g., Eastern Cooperative Oncology Group \[ECOG\] score or Karnofsky score)
Must have an index date at least 3 months prior to the start of data collection (in order to include patients with at least 3 months of follow-up after index date), unless date of death occurred less than three months from index date
Must have an approved waiver of informed consent or signed informed consent for participation in the retrospective chart review study, as applicable
You may not be if
Known primary driver alteration other than RET (e.g., targetable mutation in EGFR, ALK, ROS1, or BRAF)
History of other malignancy, other than non-melanoma skin cancer, within 1 year prior to initiation of first systemic therapy
Received pralsetinib as the first line of systemic therapy for RET-fusion positive NSCLC, or prior to initiation of first systemic therapy
